| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/18/2002 | WO2002031145A1 Novel g protein-coupled receptor protein and dna thereof |
| 04/18/2002 | WO2002031138A1 Paramyxovirus vector for transferring foreign gene into skeletal muscle |
| 04/18/2002 | WO2002031134A2 Novel serine protease genes related to dppiv |
| 04/18/2002 | WO2002031115A2 Nucleic acid molecules and polypeptides for immune modulation |
| 04/18/2002 | WO2002031109A2 Intracellular delivery of biological effectors by novel transporter peptide sequences |
| 04/18/2002 | WO2002030980A2 Use of anti-human integrin alpha d antibodies to treat spinal cord injury |
| 04/18/2002 | WO2002030956A1 N-alkylglycine trimeres capable of blocking the response to chemical substances, heat stimuli or mediators of neuronal receptor inflammation and compositions containing said trimeres |
| 04/18/2002 | WO2002030938A1 Benzhydryl derivatives |
| 04/18/2002 | WO2002030937A2 Labeled resiniferatoxin derivatives for use in vanilloid receptor binding assay |
| 04/18/2002 | WO2002030936A1 Pyrrole-condensed morphinoid derivatives |
| 04/18/2002 | WO2002030935A1 Morphinoid derivatives as delta-opioid agonists and antagonists |
| 04/18/2002 | WO2002030933A1 Substituted 3.4-dihydro-pyrido[1,2-a]pyrimidines |
| 04/18/2002 | WO2002030924A1 Quinazoline derivatives with anti-tumour activity |
| 04/18/2002 | WO2002030923A1 Novel aminotriazolone compounds, method for preparing same and pharmaceutical compositions containing same |
| 04/18/2002 | WO2002030912A1 Benzodiazepine derivatives as inhibitors of gamma secretase |
| 04/18/2002 | WO2002030911A1 Pyrimidinone derivatives and their use in the treatment of atherosclerosis |
| 04/18/2002 | WO2002030908A1 Inhibitors of protein kinases |
| 04/18/2002 | WO2002030902A1 Crystal forms of 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]piperazine.hydrochloride |
| 04/18/2002 | WO2002030898A1 N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr33 receptor antagonists |
| 04/18/2002 | WO2002030897A2 Compositions and methods for regulating the nervous system |
| 04/18/2002 | WO2002030895A1 SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-η BINDING AGENTS |
| 04/18/2002 | WO2002030888A2 Tricyclic compounds and uses thereof |
| 04/18/2002 | WO2002030884A2 Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
| 04/18/2002 | WO2002030882A2 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| 04/18/2002 | WO2002030881A1 Sulfonylguanidine |
| 04/18/2002 | WO2002030876A2 Cyclic carboxylic acids as integrin antagonists |
| 04/18/2002 | WO2002030875A1 Beta-amino acid derivatives as integrin receptor antagonists |
| 04/18/2002 | WO2002030870A2 Substituted c-cyclohexylmethylamine derivatives |
| 04/18/2002 | WO2002030868A1 Selective maxi-k- potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof |
| 04/18/2002 | WO2002030863A2 Ether compounds and compositions for cholesterol management and related uses |
| 04/18/2002 | WO2002030860A2 Ketone compounds and compositions for cholesterol management and related uses |
| 04/18/2002 | WO2002030455A2 Agents for the treatment of viral infections |
| 04/18/2002 | WO2002030448A2 Treatment of demyelinating diseases by administering gpe |
| 04/18/2002 | WO2002030447A2 Treatment of demyelinating diseases by administering gpe |
| 04/18/2002 | WO2002030428A1 Use of substituted imidazo[1,2-a]pyridine-, imidazo[1,2-a]pyrimidine and imidazo[1,2-a]pyrazine-3-yl-amine derivatives for producing nos-inhibiting medicaments |
| 04/18/2002 | WO2002030423A1 NF-λB INHIBITORS |
| 04/18/2002 | WO2002030414A1 Compositions comprising modafinil compounds |
| 04/18/2002 | WO2002030413A1 Pharmaceutical solutions of modafinil compounds |
| 04/18/2002 | WO2002030409A2 Methods for the treatment of a traumatic central nervous system injury |
| 04/18/2002 | WO2002030408A2 Compositions comprising phospholipase c inhibitors and methods for enhancing paracellular permeability across epithelial and endothelial barriers |
| 04/18/2002 | WO2002030407A1 ESTROGEN RECEPTOR-β LIGANDS |
| 04/18/2002 | WO2002030405A2 Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance |
| 04/18/2002 | WO2002030377A2 Product for cleaning teeth and/or the mouth |
| 04/18/2002 | WO2002030354A2 Uridine therapy for patients with elevated purine levels |
| 04/18/2002 | WO2002030353A2 NF-λB INHIBITORS |
| 04/18/2002 | WO2002017914A3 Fused pyrrolocarbazoles against inflammation |
| 04/18/2002 | WO2002012210A9 Biphenyl derivatives and their use as ppar-gamma receptor activators |
| 04/18/2002 | WO2002011742A3 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
| 04/18/2002 | WO2002011740A3 'slow release' pharmaceutical compositions comprising lithium carbonate |
| 04/18/2002 | WO2002008272A3 High affinity soluble interleukin-18 receptor |
| 04/18/2002 | WO2002008217A3 COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS |
| 04/18/2002 | WO2002002541A3 Inhibitors of copper-containing amine oxidases |
| 04/18/2002 | WO2001091732A3 Medicament for combating respiratory depression |
| 04/18/2002 | WO2001087830A3 Substituted thioacetamides |
| 04/18/2002 | WO2001072777A3 Human transcription factors |
| 04/18/2002 | WO2001068570A3 Il-8 receptor antagonists |
| 04/18/2002 | WO2001068569A3 Il-8 receptor antagonists |
| 04/18/2002 | WO2001068075A3 Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals |
| 04/18/2002 | WO2001066595A3 Human fgf-23 gene and gene expression products |
| 04/18/2002 | WO2001064876A3 Human schizophrenia gene |
| 04/18/2002 | WO2001064681A3 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors |
| 04/18/2002 | WO2001058916A3 Antibodies to ccr5 |
| 04/18/2002 | WO2001058893A3 Indol-3-yl derivatives and their use as integrin inhibitors |
| 04/18/2002 | WO2001051520A3 Nogo receptor-mediated blockade of axonal growth |
| 04/18/2002 | WO2001026656A3 5-membered heterocycle derivatives and use thereof as monoamine oxidase inhibitors |
| 04/18/2002 | WO2001025437A3 Growth factor polypeptides and nucleic acids encoding same |
| 04/18/2002 | WO2000073482A9 Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders |
| 04/18/2002 | WO2000068387A9 Nucleic acids and proteins with interferon-beta activity |
| 04/18/2002 | US20020045747 Treating Alzheimer's disease both prophylactically and therapeutically |
| 04/18/2002 | US20020045662 Stable gabapentin having pH within a controlled range |
| 04/18/2002 | US20020045660 For enhancing neurological development of preterm infants; arachidonic acid and/or docosahexaenoic acid; enhances visual, language and motor development without anthropomethric growth inhibition |
| 04/18/2002 | US20020045651 Pharmaceutical compositions containing triazolones and methods of treating neurodegenerative disease using triazolones |
| 04/18/2002 | US20020045644 2-phenylpyran-4-one derivatives |
| 04/18/2002 | US20020045642 Antiinflammatory, -arthritic and -emetic agents; central nervous system disorders; Parkinson's disease; antidepressants; psychological disorders; anxiolytic agents; antagonists of substance P receptors |
| 04/18/2002 | US20020045641 Multiple heteroatom containing heterocyclic ring compounds substituted with carboxylic acids and isosteres thereof |
| 04/18/2002 | US20020045639 Combination of huperzine and nicotinic compounds as a neuroprotective agent |
| 04/18/2002 | US20020045637 Novel 20,21-dinor-eburnamenine |
| 04/18/2002 | US20020045635 Novel mGluR antagonists and a method for their synthesis |
| 04/18/2002 | US20020045629 Sleep, eating and brain disorders, wakefulness promoters; Parkinson's disease, antiischemic agents, stroke, chronic fatigue syndrome; antidepressants; schizophrenia, nervous system disorders; multiple sclerosis, cognition activators |
| 04/18/2002 | US20020045624 Treatment of central nervous system (CNS) dysfunctions, neurodegenerative diseases and neurotoxic injury following hypoxia, anoxia or ischemia of stroke, cardiac arrest or perinatal asphyxia; antipsychotic and -convulsant agents |
| 04/18/2002 | US20020045623 Stable; potent; penetrates cell membranes; effectively hinders cellular apoptosis; Antiinflammatory agents, Ischemic agents, cancer, autoimmune diseases and nervous system disorders. |
| 04/18/2002 | US20020045621 A mobile ionophore composition effective to modulate APP catabolism without substantially altering the viability of APP-containing cells; inhibits amyloid deposition; Alzheimer's disease; nontoxic |
| 04/18/2002 | US20020045618 Heteroaryl diazacycloalkanes, their preparation and use |
| 04/18/2002 | US20020045617 Act preferentially on M4 receptors; side effect reduction; used to treat nervous system disorders, psychological disorders and as an analgesic; Alzheimer's disease; Cognition activators. |
| 04/18/2002 | US20020045615 Benzothiazole derivatives with activity as adenosine receptor ligands |
| 04/18/2002 | US20020045614 1-(4-(((4-Amino-6,7-dimethoxy-quinazolin-2-yl)-methyl-amino) methyl)-4-phenyl-piperidin-1-yl)-1-cyclopropyl-methanone; treating disease states ameliorated by blockade of alpha-1 adrenoceptors; sleep/psychological disorders |
| 04/18/2002 | US20020045613 1-aroyl-piperidinyl benzamidines |
| 04/18/2002 | US20020045608 Drug addiction, drug dependence |
| 04/18/2002 | US20020045595 N6 heterocyclic 8-modified adenosine derivatives |
| 04/18/2002 | US20020045577 Human schizophrenia gene |
| 04/18/2002 | US20020045568 Use of mp52 0r mp121 for treating and preventing diseases of the nervous system |
| 04/18/2002 | US20020045566 Selective maxi-K potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof |
| 04/18/2002 | US20020045264 Expression vectors for use in gene therapy |
| 04/18/2002 | US20020045229 Nucleotide sequences coding membrane protein for use inthe treatment of epilepsey, arrhythmia, and pain in humans |
| 04/18/2002 | US20020045213 IL-17 receptor like molecules and uses thereof |
| 04/18/2002 | US20020045206 Contacting the cells with a trophic amount of a ptc therapeutic for promoting survival of substantia nigra neuronal cells |
| 04/18/2002 | US20020045203 Method for detecting active ingredients of medical value |
| 04/18/2002 | US20020045201 Sreening drugs for use in treatment of nervous system disorders; obtain protein sample, mix with modulator, monitor complex formation, compare to control, adjustment in concentration of preferential complex indicates modulator |
| 04/18/2002 | US20020044966 Pharmaceutical formulations containing an opioid and an alpha-agonist |
| 04/18/2002 | US20020044925 Myoblast transfer therapy for relieving pain and for treating behavioral and perceptive abnormalities |